PL3452507T3 - Immunoterapia tau - Google Patents

Immunoterapia tau

Info

Publication number
PL3452507T3
PL3452507T3 PL17723767.4T PL17723767T PL3452507T3 PL 3452507 T3 PL3452507 T3 PL 3452507T3 PL 17723767 T PL17723767 T PL 17723767T PL 3452507 T3 PL3452507 T3 PL 3452507T3
Authority
PL
Poland
Prior art keywords
tau immunotherapy
tau
immunotherapy
Prior art date
Application number
PL17723767.4T
Other languages
English (en)
Inventor
Peter Seubert
Philip James DOLAN III
Yue Liu
Robin Barbour
Original Assignee
Prothena Biosciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Limited filed Critical Prothena Biosciences Limited
Publication of PL3452507T3 publication Critical patent/PL3452507T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL17723767.4T 2016-05-02 2017-05-02 Immunoterapia tau PL3452507T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330786P 2016-05-02 2016-05-02
PCT/IB2017/052543 WO2017191559A1 (en) 2016-05-02 2017-05-02 Tau immunotherapy

Publications (1)

Publication Number Publication Date
PL3452507T3 true PL3452507T3 (pl) 2023-01-09

Family

ID=58709514

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17723767.4T PL3452507T3 (pl) 2016-05-02 2017-05-02 Immunoterapia tau

Country Status (13)

Country Link
US (3) US10752679B2 (pl)
EP (1) EP3452507B1 (pl)
JP (2) JP7170316B2 (pl)
KR (1) KR102506091B1 (pl)
CN (1) CN109415432B (pl)
CA (1) CA3022673A1 (pl)
DK (1) DK3452507T3 (pl)
ES (1) ES2933491T3 (pl)
FI (1) FI3452507T3 (pl)
HU (1) HUE060258T2 (pl)
PL (1) PL3452507T3 (pl)
PT (1) PT3452507T (pl)
WO (1) WO2017191559A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
PE20190261A1 (es) 2016-05-02 2019-02-25 Prothena Biosciences Ltd Anticuerpos que reconocen tau
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
WO2017191561A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
EP3976793A4 (en) * 2019-05-27 2023-06-21 The University of British Columbia CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES AGAINST IT AND METHODS RELATED THERETO
CA3178760A1 (en) 2020-05-19 2021-11-25 Robin Barbour Multi-epitope vaccine for the treatment of alzheimer's disease
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US101A (en) 1836-12-06 Method of jcakibtg and furling iw sails fob ships
US5530A (en) 1848-04-25 Horse-power
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
EP2192131A1 (en) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
DK0673418T3 (da) 1992-12-14 1999-03-01 Innogenetics Nv Monoklonale antistoffer rettet mod mikrotubulusassocieret tau-protein, hybridomaer, der secernerer disse antistoffer, antig
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
WO2000046750A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
CA2491864C (en) 2001-07-12 2012-09-11 Jefferson Foote Super humanized antibodies
DE60334460D1 (de) 2002-08-14 2010-11-18 Mitsubishi Chem Medience Corp Antikörper spezifisch für das tau-protein des zentralen nervensystems
DK1567652T3 (da) 2002-11-29 2007-11-26 Boehringer Ingelheim Pharma Nye neomycin-phosphotransferasegener og fremgangsmåde til selektion af höjtproducerende rekombinante celler
US7847146B2 (en) 2003-03-28 2010-12-07 Baylor College Of Medicine Model for neurodegenerative disorders
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US20050132424A1 (en) 2003-10-21 2005-06-16 Envivo Pharmaceuticals, Inc. Transgenic flies expressing Abeta42-Dutch
WO2006037604A1 (en) 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
DE602005026706D1 (de) 2004-12-30 2011-04-14 Us Government Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
KR20090019864A (ko) 2006-06-16 2009-02-25 엔비보 파마슈티칼즈, 인코퍼레이티드 Ｔａｕ와 아밀로이드 전구체 단편을 발현하는 유전자도입 파리
CA2655379A1 (en) 2006-06-22 2007-12-27 Walter And Eliza Hall Institute Of Medical Research Structure of the insulin receptor ectodomain
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
WO2008022153A2 (en) 2006-08-14 2008-02-21 The Regents Of The University Of California Inhibitors of pde4 and methods of use
MX2009005776A (es) 2006-12-01 2009-06-10 Medarex Inc Anticuerpos humanos que se enlazan al cd 22 y sus usos.
EP2118300B1 (en) 2007-02-23 2015-05-27 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
EA018190B1 (ru) 2007-03-02 2013-06-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Улучшение производства белков
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP2009056790A (ja) 2007-09-03 2009-03-19 Takao Otogawa ファイル用ポケット
SG187477A1 (en) 2007-09-26 2013-02-28 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
EA020886B1 (ru) 2007-11-13 2015-02-27 ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. Гуманизированные антитела против tl1a
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
JP2010014691A (ja) 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
BRPI0916973A2 (pt) 2008-08-18 2016-07-26 Amgen Fremont Inc anticorpos para ccr2
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
TWI529247B (zh) 2009-05-13 2016-04-11 建新公司 抗人類ｃｄ５２免疫球蛋白
EP3329932A1 (en) 2009-06-10 2018-06-06 New York University Immunological targeting of pathological tau proteins
US20110045534A1 (en) 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
EP2470211B1 (en) 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Antibodies that bind tau oligomers
WO2011053565A2 (en) 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
AU2010330794A1 (en) 2009-12-18 2012-06-21 Amgen Inc. Wise binding agents and epitopes
JP5697044B2 (ja) 2010-01-08 2015-04-08 国立大学法人京都大学 タウオパチー治療用ワクチン
AR080243A1 (es) 2010-02-23 2012-03-21 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
JP2011201655A (ja) 2010-03-25 2011-10-13 Minoru Industrial Co Ltd ダンボールテープ貼付機
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
EP2560681A4 (en) 2010-04-22 2013-09-25 Janssen Alzheimer Immunotherap USE OF TAU FOR MONITORING IMMUNOTHERAPY
ITRM20100320A1 (it) 2010-06-11 2011-12-11 Consiglio Nazionale Ricerche Metodo per la diagnostica e il trattamento delle taupatie
US20120023911A1 (en) 2010-07-28 2012-02-02 Gm Global Technology Operations, Inc. Detection of exhaust particulate filter substrate failure
WO2012049570A1 (en) 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Human anti-tau antibodies
EP2673635A4 (en) 2011-02-07 2015-08-12 Neotope Biosciences Ltd IMMUNOTHERAPY THROUGH APOE
WO2012149365A2 (en) 2011-04-27 2012-11-01 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
SG10201804809RA (en) 2011-08-22 2018-07-30 Cnj Holdings Inc Clostridium difficile antibodies
DK2758433T3 (en) 2011-09-19 2018-01-15 Axon Neuroscience Se PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY OF ALZHEIMER'S DISEASE
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2764022B9 (en) 2011-10-07 2017-02-22 AC Immune S.A. Phosphospecific antibodies recognising tau
WO2013059786A1 (en) 2011-10-21 2013-04-25 The Ohio State University Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
PT2831113T (pt) 2012-03-28 2018-06-20 Sanofi Sa Anticorpos para ligandos do recetor b1 da bradicinina
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
US9428864B2 (en) 2012-04-18 2016-08-30 E I Du Pont De Nemours And Company Multilayered sheet
DE102012211455A1 (de) 2012-07-02 2014-01-02 Wobben Properties Gmbh Handhabungsvorrichtung zum Handhaben einer Rotorblattform zum Fertigen eines Rotorblattes einer Windenergieanlage
CA2877397A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
MY176838A (en) 2012-08-16 2020-08-24 Ipierian Inc Methods of treating a tauopathy
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EP4356927A3 (en) 2012-10-12 2024-10-02 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
LT2935326T (lt) 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US9364191B2 (en) 2013-02-11 2016-06-14 University Of Rochester Method and apparatus of spectral differential phase-contrast cone-beam CT and hybrid cone-beam CT
US10501531B2 (en) * 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
CN105283196B (zh) 2013-03-15 2018-10-12 贝丝以色列女执事医疗中心 用于产生和使用构象-特异性抗体的方法和组合物
EP3418430B1 (en) 2013-03-15 2023-03-29 The Trustees of the University of Pennsylvania Blood biomarkers that predict persistent cognitive dysfunction after concussion
US20150056199A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
US20160289309A1 (en) 2013-11-27 2016-10-06 Ipierian, Inc. Methods of treating a tauopathy
WO2015089375A1 (en) 2013-12-13 2015-06-18 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
MX2016007958A (es) 2013-12-17 2016-08-03 Genentech Inc Anticuerpos anti-cd3 y metodos de uso.
US9629801B2 (en) 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US20150253341A1 (en) 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
WO2015197823A2 (en) 2014-06-26 2015-12-30 Crucell Holland B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
SG11201703237VA (en) 2014-11-19 2017-06-29 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US10202444B2 (en) 2015-02-24 2019-02-12 Rpeptide, Llc Anti-tau antibodies
WO2016196726A1 (en) 2015-06-05 2016-12-08 Genentech, Inc. Anti-tau antibodies and methods of use
US20200030445A1 (en) 2015-06-12 2020-01-30 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
PE20180499A1 (es) 2015-07-06 2018-03-09 Ucb Biopharma Sprl Anticuerpos de union a tau
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CN107849125A (zh) 2015-07-21 2018-03-27 生命北极神经科学公司 用于治疗靶向聚集的肽的创伤性脑损伤的方法
JP2018537956A (ja) 2015-10-06 2018-12-27 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
US10752679B2 (en) * 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
WO2017191561A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
PE20190261A1 (es) 2016-05-02 2019-02-25 Prothena Biosciences Ltd Anticuerpos que reconocen tau
US10947302B2 (en) 2016-11-04 2021-03-16 The Regents Of The University Of California Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
WO2018106781A1 (en) 2016-12-07 2018-06-14 Genentech, Inc Anti-tau antibodies and methods of use
WO2018106776A2 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
CN110545844A (zh) 2017-02-21 2019-12-06 瑞美德生物医药科技有限公司 使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
EP3601335A1 (en) 2017-03-28 2020-02-05 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
SG10201911225WA (en) 2017-03-28 2020-01-30 Genentech Inc Methods of treating neurodegenerative diseases
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
EP3638694A1 (en) 2017-06-16 2020-04-22 Bristol-Myers Squibb Company Compositions and methods for treating tauopathies
AU2018352308A1 (en) 2017-10-16 2020-03-19 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
US20200369754A1 (en) 2017-12-04 2020-11-26 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
TW202003036A (zh) 2018-03-23 2020-01-16 德商艾伯維德國有限及兩合公司 穩定水性抗-tau抗體調配物
EP3774887A2 (en) 2018-03-28 2021-02-17 Axon Neuroscience SE Antibody-based methods of detecting and treating alzheimer's disease
EP3784274A1 (en) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US20220153821A1 (en) 2018-11-08 2022-05-19 Prothena Biosciences Limited Antibodies recognizing tau
CA3118818A1 (en) 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
EP3883602A4 (en) 2018-11-19 2023-04-12 The Board Of Regents Of The University Of Texas System TAU PEPTIDE ANTIGENS AND ANTIBODIES BINDING TO THEM FOR THE TREATMENT OF TAUOPATHIES
US20220275067A1 (en) 2019-02-08 2022-09-01 Prothena Biosciences Limited Antibodies recognizing tau
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
US20220177558A1 (en) 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
BR112022000719A2 (pt) 2019-07-15 2022-03-29 Adel Inc Anticorpo anti-tau ou um fragmento de ligação ao antígeno do mesmo, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do anticorpo anti-tau ou fragmento de ligação ao antígeno do mesmo, hibridoma, composição farmacêutica, composição para diagnosticar uma doença neurológica degenerativa, kit, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo e método para prevenir ou tratar uma doença neurológica degenerativa

Also Published As

Publication number Publication date
JP7170316B2 (ja) 2022-11-14
JP7405459B2 (ja) 2023-12-26
US11492393B2 (en) 2022-11-08
WO2017191559A1 (en) 2017-11-09
US20210032319A1 (en) 2021-02-04
DK3452507T3 (da) 2022-11-14
CN109415432A (zh) 2019-03-01
US10752679B2 (en) 2020-08-25
JP2022116136A (ja) 2022-08-09
PT3452507T (pt) 2022-12-20
KR102506091B1 (ko) 2023-03-07
EP3452507B1 (en) 2022-10-19
CN109415432B (zh) 2022-07-08
ES2933491T3 (es) 2023-02-09
HUE060258T2 (hu) 2023-02-28
CA3022673A1 (en) 2017-11-09
US20190322728A1 (en) 2019-10-24
EP3452507A1 (en) 2019-03-13
JP2019521649A (ja) 2019-08-08
KR20190015705A (ko) 2019-02-14
US20230126858A1 (en) 2023-04-27
FI3452507T3 (fi) 2022-12-15

Similar Documents

Publication Publication Date Title
GB201803228D0 (en) No title
GB201710488D0 (en) No title
PT3452507T (pt) Imunoterapia anti-tau
GB201717200D0 (en) No title
GB201710482D0 (en) No title
GB201713006D0 (en) No title
IL259793A (en) slc45a2 peptides for immunotherapy
GB201716372D0 (en) No title
GB201803011D0 (en) No Title
PT3107573T (pt) Imunoterapia com il-12 visada ao cancro
EP3215182A4 (en) Combination immunotherapy
HK1254601A1 (zh) 新型肽
PL3512537T3 (pl) Immunoterapia limfocytami t
GB201710485D0 (en) No title
GB201704436D0 (en) No Title
GB201701373D0 (en) Foriegn title
GB201710479D0 (en) No title
GB201802962D0 (en) No Title
GB201704324D0 (en) No title
GB201701370D0 (en) Foriegn title
GB201605264D0 (en) No title
GB201702268D0 (en) No details available
GB201621588D0 (en) No title
GB201807152D0 (en) No title
GB201715203D0 (en) Novel methods